Subacute Cervical Pain Clinical Trial
Official title:
The Therapeutic Use of Botulinum Toxin Type A in Subacute Cervical/Upper Back Pain
To determine the therapeutic efficacy of Botox not only for chronic cervical/upper back pain but also for subacute pain.
Status | Completed |
Enrollment | 0 |
Est. completion date | July 2006 |
Est. primary completion date | |
Accepts healthy volunteers | |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Male or female 18 y/o or greater, - Subacute bilateral cervical/ upper back pain, pain of longer than 2 months and shorter than 6 months duration, - VAS pain score of 5 or greater for the cervical/ upper back pain for 4 week period before injection, - If female or child bearing potential, concurrent use of a reliable method of contraception. Exclusion Criteria: - Known allergy or sensitivity to Botulinum toxin type A. - Any medical condition that may put the subject at increased risk with exposure to BOTOX®, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other significant disease that might interfere with neuromuscular function - Use of aminoglycoside antibiotics, curare-like agents, or other agents that might interfere with neuromuscular function - Pregnancy, breast feeding, or planned pregnancy - Acute or operative pathology on cervical MRI - History of treatment for gatro-esophageal reflux disease - Abnormal finding on 3-oz water swallowing test on the initial screening visit |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Palo Alto Veterans Institute for Research | Allergan |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | NDI, VAS, SF-36 |